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Abstract
Background: The expression and activity of P-glycoproteins due to genetic or environmental
factors may have a significant impact on drug disposition, drug effectiveness or drug toxicity. Hence,
characterization of drug disposition over a wide range of conditions of these membrane
transporters activities is required to better characterize drug pharmacokinetics and pharmaco-
dynamics. This work aims to improve our understanding of the impact of P-gp activity modulation
on tissue distribution of P-gp substrate.
Methods: A PBPK model was developed in order to examine activity and expression of P-gp
transporters in mouse brain and heart. Drug distribution in these tissues was first represented by a well-
stirred (WS) model and then refined by a mechanistic transport-based (MTB) model that includes P-gp
mediated transport of the drug. To estimate transport-related parameters, we developed an original
three-step procedure that allowed extrapolation of in vitro measurements of drug permeability to the in
vivo situation.The model simulationswerecompared to a limited setofdata inorder to assessthe model
ability to reproduce the important information of drug distributions in the considered tissues.
Results: This PBPK model brings insights into the mechanism of drug distribution in non
eliminating tissues expressing P-gp. The MTB model accounts for the main transport mechanisms
involved in drug distribution in heart and brain. It points out to the protective role of P-gp at the
blood-brain barrier and represents thus a noticeable improvement over the WS model.
Conclusion: Being built prior to in vivo data, this approach brings an interesting alternative to
fitting procedures, and could be adapted to different drugs and transporters.
The physiological based model is novel and unique and brought effective information on drug
transporters.
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The most studied ATP binding cassette (ABC) membrane
transporters is the P-glycoprotein (P-gp), which is a
multidrug resistance (MDR) protein encoded by the
ATP-binding cassette B1 (ABCB1) gene. The important
role of P-gp in drug absorption and excretion in
intestine, kidney and liver, has been revealed through
reduction of absorption of orally administered drugs and
promotion of urinary and biliary excretion [1, 2].
Furthermore, P-gp transporters have a regulator function
by limiting penetration of drugs in brain, heart, placenta,
ovaries, and testes tissues. This has been shown in vivo on
wild type (WT), mdr1a(-) and mdr1a/1b(-/-) knockout
(KO) mice, which are mice lacking genes encoding for
drug-transporting P-gp [3]. Indeed, higher levels of
radioactivity were measured in various tissues of simple
or double mutated mice compared to WT mice, after IV
or oral administration of different P-gp substrates [3-8].
It has been demonstrated that modulation of the
expression and/or activity of these transporters due to
genetic or environmental factors may have a significant
impact on drug disposition, drug effectiveness or drug
toxicity [9-11]. Hence, characterization of drug disposi-
tion over a wide range of conditions of ABC membrane
transporters activities is required to better characterize
drug pharmacokinetics and pharmacodynamics.
Among pharmacokinetic modeling approaches, the phy-
siologically based pharmacokinetic (PBPK) approach is
now progressively usedat variousstages of drug discovery
and development. PBPK models are developed to predict
xenobiotic disposition throughout a mammalian body.
By characterizing the kinetic processes of the drug, it is
possible to predict its distribution inside tissues, organs
and fluids of the body. The whole-body PBPK model
involving tissues and organs connected via the vascular
system mimics the anatomical structure of the mammal
being studied. Generally, tissue distribution of drugs can
be represented either by the perfusion rate limited (also
called well-stirred) model, or the permeability rate
limited model. The former assumes an instantaneous
and homogenous drug distribution in tissues, whereas
the latter represents the tissue as two or three well-stirred
compartments which are separated by a capillary and/or
cellular membrane where a permeability rate limited
transfer occurs [12]. However, the membrane perme-
ability may not be the only factor contributing towards
limitation of drug distribution within a tissue. The influx
or efflux activity of ABC transporters can be another
important factor involved in drug distribution and
should be considered as such in PBPK modeling.
In drug research and development, predicting drug disposi-
tion prior to in vivo studies is a major challenge [13]. Within
this context, the hypothesis-driven strategy adopted here is
tobuild adata-independent modelthat minimizesrecourse
todatafittingandexploits invitro datainformation. Indeed,
the spirit of PBPK modeling is deeply rooted in the
independence of the model building on the output data
representing the process to be described. It is based on the
integration within a whole entity of drug specific character-
istics with a structural mode which can be more or less
detailed in terms of tissues and organs to be included. As
relevant knowledge of the physiological, morphological,
andphysicochemicaldatabecomesavailable,thepossibility
exists for efficient use of limited data in order to reasonably
describethepharmacokineticsofspecificcompoundsunder
a variety of conditions [14]. With this in mind, the whole-
body PBPK model developed herein aims to shed light,
prior to in vivo experiments, on drug distribution in tissues
expressing P-gp transporters. For this purpose, we adopt a
stepbystepprocedurewhichledustothefinalPBPKmodel
applied to mice, which accounts for the P-gp-mediated
efflux transport in heart, and brain tissues. We first use the
WS model to represent the drug distribution in each tissue.
Then, to account for both passive and active transports, a
mechanistic transport-based (MTB) model is developed for
heart and brain. In order to estimate transport-related
parameters all the while minimizing data fitting, we
developed a method to extrapolate in vitro measurements
of drug permeability of P-gp substrates through endothelial
cells monolayers to the in vivo situation. This allowed the
estimation of those parameters related to apparent passive
and active transport of the drug through blood-tissue
membrane of brain and heart.
To appreciate the reliability of the knowledge that the
model provides in terms of elucidating the impact of the
modulation of P-gp activity on drug distribution, we had
access to WT and KO tissue concentrations of domper-
idone, an antiemetic drug associated with cardiac toxicity
[15-17]. The choice of this drug model was motivated by
previous in vitro results [18], which suggested that
domperidone could be highly transported by P-gp.
While this data set cannot be considered rich enough
to validate the developed PBPK model, it can at least
show that, the model simulations lie within realistic
values by capturing points in the main strategic regions
of the tissue concentration profiles, namely at the
maximum concentration and the elimination phase.
Methods
Structure of the PBPK model
The present investigation focuses on P-gp substrate dis-
tributioninheartandbraintissuewherethistransporterhas
a protective function. Our whole body PBPK model
included these tissues as well as core tissues, organs and
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the adipose tissue because of its involvement in the
disposition of lipophilic drugs. To make the model readily
usable for subsequent updates and future experimental
data, we also included bone, gut, lung, kidneys, muscle skin
and spleen in the PBPK structure (Figure 1).
The PBPK model is mathematically formulated as a set of
ordinary differential equations of mass balance that
represents the time dependent variation of the drug
concentrationineachtissue.Wesystematicallyperformed
an overall mass balance of the whole-body PBPK model
to assure that mass conservation laws are respected.
Tissue-distribution models
The parameters used in the equations presented in this
section refer to concentration (C), volume (V), blood
flow to tissue (Q), tissue:plasma partition coefficient
(Ptp), blood:plasma ratio (BP), unbound fraction of drug
(fu), clearance (CL), and permeability-surface area
product (PSA). The subscripts refer to cardiac output
(co), tissue (t), kidneys (k), spleen (sp), gut (g), plasma
(p), liver (li), lung (lg), heart (ht), arterial blood (ab),
venous blood (vb), blood in equilibrium with tissue
(bl), venous blood living tissue (v, t), unbound fraction
(u), bound fraction (b), intracellular water (iw), extra-
cellular water (ew), neutral lipid (nl), neutral phospho-
lipid (np), and microsomal binding (mic). Some
subscripts refer to active transport processes, such as P-
gp mediated transport (P-gp), as well as other
transporters (OT) such as influx transporters (in, OT)
and additional efflux transporters (out, OT).
Well-stirred model (WS)
At this first step of model development, the whole-body
PBPK model is based on perfusion limited model of
disposition. The uptake rate of the drug into tissues is
limited by the flow rate to tissue rather than the
diffusion rate across cell membranes [19]. In this case,
the unbound concentration of drug in tissue is in
equilibrium with the unbound drug in the outcoming
blood. The application of a WS model requires the
tissue-to-plasma partition coefficient (Ptp) of each tissue
included in the PBPK model as input parameters. By
definition, these partition coefficients were calculated as:
P
CT
Cp
Cut
Cup
fup
fut
fu Kp tp,t p u == = ⋅ (1)
where Kpu is the unbound tissue-to plasma partition
coefficient [20] calculated from the tissue-composition-
based approach developed by Rodgers et al. [20].
The hepatic elimination is determined from intrinsic
clearance (CLint), such as
CL
Vmax P450
Km(P450)
N int CYP450 = ()
× (2)
where Vmax(P450) and Km(P450) are the Michaelis Menten
parameters of drug biotransformation measured in mice
hepatic pooled microsomes, and NCYP450 (nmol) is the
amount of mice hepatic cytochrome P450.
The conventional description of hepatic extraction ratio
(Eh) corresponds to (CLint *f u p/fumic)/(CLint *f u p/fumic
+Q h) for a well-stirred liver model [21], where fumic is
the fraction of drug unbound to hepatic microsomes
which can be estimated as follows for a basic drug [22]:
Fumic =( C mic·10
0.56·LogP-1.41+1 )
-1 (3)
where Cmic is the microsomal protein concentration (20
mg microsomal protein/mL herein), and LogP is the
octanol:water partition coefficient of the drug.
The mass balance equations of the WS model applied to
the tissues included in the PBPK model are [23]:
￿ non-eliminating tissues:
V
dCt
dt
QCC t t ab v,t ×= ×− ()(4)
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Schematic representation of the procedures used to
develop the whole body PBPK model applied to the
mouse (30 g BW) following a 5 mg/kg IV injection of
domperidone.
Theoretical Biology and Medical Modelling 2009, 6:2 http://www.tbiomed.com/content/6/1/2
Page 3 of 13
(page number not for citation purposes)￿ eliminating tissues (liver)
V
dCli
dt
QQ Q C Q C QC
fup
fumic
CL
li li sp g ab spl v,spl g v,g ×= − − () ×+ × + ×
− i int v,li li v,li CQ C ⋅− ×
(5)
where CLint and fumic are estimated from equation 2 and
3 respectively.
￿ arterial blood
V
dCab
dt
QCC ab co v,lg ab ×= ×− () (6)
￿ venous blood
V
dCvb
dt
QC Q C vb t v,t
t
co vb ×= × () −× ∑ (7)
￿ lung
V
dClg
dt
QC C lg co vb v,lg ×= × − () (8)
with 
Cx BP
Ptp,x
 where x stands for t, sp, li and lg Cv,x =
×
.
(9)
Mechanistic Transport-Based (MTB) models
We propose a transport-based tissue model to mechan-
istically investigate drug distribution in non-eliminating
tissues expressing active transporters. This tissue model
accounts for apparent passive diffusion and active
transports of the drug at the blood-tissue membrane.
Since only limited transport-related information is
available within extra-and intra-cellular space of a tissue,
it has been resumed by the transport occurring at the
capillary membrane. This choice has the advantage to
minimize the recourse to fitting procedures of transport-
related parameters that would have been required in a
three sub-compartmental tissue model. Thus, we
assigned the term 'apparent' to the transport-related
parameters and divided the tissue in two well-stirred
compartments representing the vascular and extravascu-
lar tissues, separated by a capillary membrane where
apparent diffusion and apparent active transports of the
unbound drug occur. The fraction of drug unbound to
tissue was calculated from the total tissue concentration
CT estimated from the method developed by Rodgers
a n dR o w l a n d[ 2 0 ] .I n d e e d ,C T c a nb ee x p r e s s e di nt e r m s
of the unbound concentration in intracellular and
extracellular water, and of the drug concentration
bound to neutral lipid and phospholipids, such as [20]:
CT =C u, iw·fiw +C u, ew·few +C b, nl·fnl +C b, np·fnp(10)
The unbound drug fraction in tissues (fut) was calculated
by rearranging Equation 10, such as
fu
Cut
CT
fiw Cuiw few Cuew
CT
t ==
⋅+ ⋅
(11)
Remembering that Cuew equals to the unbound con-
centration in plasma (Cup), and Cuiw for a monoprotic
base is given by [20]:
Cu Cu
X
Y
iw p =⋅ (12)
with
X=1+1 0
(pKa-pHiw) (13)
Y=1+1 0
(pKa-pH) (14)
Then, using equations 1, 11 and 12, fut can be expressed
as:
fu
fiw
X
Y
few
Kpu
t =
⋅⎛
⎝
⎜
⎞
⎠
⎟+
(15)
where fiw i st h ef r a c t i o n a lt i s s u ev o l u m eo fi n t r a c e l l u l a r
water and few fractional tissue volume of extracellular
water. We used published tissue specific data [20], and
assumed that the tissue composition in protein is the
same among rodent (Table 1).
The active transports include, but are not limited to,
apparent P-gp mediated efflux of the unbound drug
from tissue to blood. This general mechanistic transport-
based model can also account for additional efflux
(CLout, OT)a n d / o ri n f l u x( C L in, OT) transporters. We first
only consider the contribution of apparent passive
diffusion and P-gp mediated transport in both tissues,
setting thus to 0 the terms CLin, OT and CLout, OT.T h e
transport-based tissue model can also be used to
investigate the involvement of additional transporters
by setting to non-zero values the parameters CLin, OT and
CLout, OT. Compared to P-gp, there is limited knowledge
for other transporters in terms of their activity and
expression in mammalian tissues [24]. Hence, influx
and/or efflux clearances of non P-gp transporters can be
extracted from the best fit of tissue-concentration data.
The general mass balance equations defining the
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brain tissues (Figure 2) are described below:
￿ Extravascular compartment (tissue)
Vt PSAt  fup Cp,t fut Ct fut Ct CLPgp,t CLout,OT
dCt
dt
×=×× − × − × × + () ()
+ +× ×  fup Cp,t CLin,OT
(16)
￿ Vascular compartment (blood)
Vbl,t Qt  Cab Cv,t PSAt  fut Ct fup Cp,t 
fut
dCv, t
dt
×= × − + × × − ×
+
() ()
× ×× + − × × () Ct CLPgp,t CLout,OT fup Cp,t CLin,OT
(17)
Mouse-related parameters
Mouse tissue composition, tissue volume, and blood-
flow rate into tissue were extracted from the literature
[25-27]; they are listed in Table 1.
The total amount of hepatic cytochrome P450 in mouse,
NCYP450, was estimated by developing a log-log regres-
sion analysis that relates the total amount of NCYP450 of
different mammalian species to their liver weight [28].
Distribution-related parameters required for the
MTB model
The volume of blood in equilibrium with brain and
heart tissues (Vbl, t) and the exchange surface area of the
mouse blood-brain barrier were directly extracted from
t h el i t e r a t u r e[ 2 9 - 3 5 ] .S u r f a c ea r e a( S t)p e rg r a mo f
cardiac tissue, only available for humans or quantifiable
from human data [36, 37], were applied to mice. As the
estimation of permeability-surface area product (PSAt)
and P-gp efflux (CLP-gp, t) clearance of a P-gp substrate
through blood-tissue membrane is a crucial information,
we have developed the following three-step procedure to
estimate these parameters for mouse brain and heart
tissue.
Step I: Estimation of in vitro diffusion and P-gp efflux rates of a
P-gp substrate through Caco-2 monolayer
Assuming the drug is mainly transported by P-gp and
used at a dose below the transporters saturation limit,
then apical to basolateral apparent permeability (Papp,
ab) of drugs through Caco-2 monolayers results from the
difference between apparent drug diffusion velocity
Table 1: Input physiological parameters used in PBPK model for IV injection of domperidone to a 30 g body weight mouse.
Tissue Composition (% of wet tissue
weight) [20]
Physiological Data
Tissues Intra
Cellular
Water
Extra
Cellular
Water
Neutral
Lipids
Phospholipids Blood Flow
Rate (% of Qc)
a
Volume
(% of BW)
Unbound
Fraction to
Tissue
b
Partition
Coefficient
c (Ptp)
Adipose
d 0.017 0.1350 0.853 0.002 0.07 0.0700 0.0079 1.7258
Bone + ROB* 0.346 0.1000 0.220 0.0005 0.218 0.0799 0.0327 2.0582
Brain 0.620 0.1620 0.031 0.05 0.031 0.0165 0.0463 2.5722
Gut 0.475 0.2820 0.032 0.015 0.141 0.0253 0.0166 6.2541
Heart 0.456 0.3200 0.017 0.014 0.066 0.0038 0.0212 4.8909
Kidney 0.483 0.2730 0.0148 0.0341 0.110 0.0135 0.0104 10.019
Liver 0.573 0.1610 0.0138 0.0303 0.161 0.042 0.0120 9.2366
Lung 0.446 0.3360 0.0218 0.0162 0.005 0.0073 0.0125 8.2560
Muscle 0.630 0.0790 0.0167 0.0273 0.159 0.384 0.0290 3.9387
Skin 0.291 0.3820 0.0239
d 0.0180
d 0.058 0.1653 0.0156 5.1585
Spleen 0.579 0.2070 0.012 0.0107 0.002
c 0.0035 0.0184 6.3008
Plasma ——0.096 0.0032 —— — —
Arterial blood ———— — 0.0272
d ——
Venous blood ———— — 0.0544
d ——
a The mouse cardiac output value was estimated from the following allometric equation: Qc = 0.235 × BW
0.75;
b Calculated from equation 7.
c Calculated from equation 1 using the method of Rodgers and Rowland [20]
d Rat value [23]; * ROB: rest of body
Figure 2
Diagrams of the mechanistic transport-based tissue
model that considers the passive transport of the
drug, the P-gp mediated efflux transport, additional
efflux transport and/or influx transport.
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Basolateral to apical apparent permeability (Papp, ba)i s
the result of the additive action of the drug diffusion
velocity along with P-gp efflux transport. Assuming that
P-gp efflux rate is independent of the direction of
diffusion, the in vitro estimation of the parameters of
apparent drug diffusion and apparent P-gp efflux rates
(Pdiff, in-vitroand PP-gp, in-vitro) are calculated as follows:
Pdiff, in-vitro  Papp, ba Papp, ab
1
2
=+ () (18)
PPgp, in-vitro  Papp, ba Papp, ab
1
2
=− () (19)
where Papp, ba and Papp, ab values can be either directly
measured through Caco-2 cells monolayers, or extracted
from the literature.
Step II: In vitro-in vivo extrapolation of drug diffusion velocity and
P-gp efflux rate parameters
We extrapolated in vitro P-gp efflux rate and diffusion
velocity of P-gp substrates to the in vivo situation (Table 2),
applying linear regressions procedures to data published by
Collett et al. [38]. Some data presented in Table 2 are also
extracted literature [39-45].
The authors measured Papp, ba and Papp, ab of some drugs
through Caco-2 cells monolayer as well as Papp, ab in the
presence of a P-gp inhibitor (GF 120918). They
determined the Michaelis-Menten kinetic parameters of
active efflux transport, Vmax(efflux) and Km(efflux),o ft h e s e
drugs. Moreover, they compared oral plasma area under
the curve (AUC) of these compounds in WT and KO
mice. In order to consider only the effect of P-gp on
intestinal absorption of drugs, we corrected the ratio of
drug AUCoral between species by removing the effect of
P-gp involved in renal and biliary clearance on AUCoral.
We first estimated the effect (EIV-P-gp) of the absence of
P-gp on AUCIV measured after IV injection, such as:
EIV-P-gp =( A U C iv(KO) -A U C iv(WT))/AUCiv(KO).( 2 0 )
Then, the corrected ratio of oral AUC between both mice
s t r a i n si sc a l c u l a t e da sf o l l o w s :
RAUCoral, corr =A U C oral, KO, corr/AUCoral, WT,=E IV-Pgp ×
AUCoral, KO,/AUCoral, WT (21)
This ratio reflects the effect of P-gp mediated efflux in gut
absorption:
R AUCcorr
AUCoral,  KO, corr
AUCoral,WT
FabsKO
FabsWT
Pdiff,  =≈ ≈ i in-vivo
Pdiff, in-vivo PPgp, in-vivo −
(22)
where Fabs is the fraction of absorbed drug through the
gastro-intestinal tract.
Then, we estimated in vivo diffusion velocity of these
P-gp substrates through gut membrane from RAUC, corr
value that we mechanistically approximated as follows:
Pdiff, in-vivo Pgp, in-vivo
RAUCcorr
RAUCcorr 1
P
RAUCcorr
RA
≈≅
−
×
U UCcorr 1
Vmax P-gp
Km P-gp   −
× ()
()
(23)
where PP-gp, vivo is approximated by the ratio Vmax(P-gp)/
Km(P-gp).
Table 2: Related parameters of the P-gp substrates used to establish linear regressions allowing the in vitro-in vivo extrapolation of
diffusion and P-gp mediated efflux rates. Data were extracted from Collett and coworkers [38].
Drug
Name
MW LogP Pappab
a, c
cm/s
Pappba
a, c
cm/s
Vmax(P-gp)/
Km(P-gp)
a, c
cm/s
Pdiffvitro
cm/s
Pdiffvivo
b
cm/s
PP-gp, vitro
cm/s
RAUCcorr
b Ref
Paclitaxel 854 3 2.1 × 10
-6 8.61 × 10
-6 2.1 × 10
-5 5.36 × 10
-6 3.04 × 10
-5 3.26 × 10
-6 3.26 [38, 39]
Digoxin 789 2.2 1.1 × 10
-6 7.15 × 10
-6 1.3 × 10
-5 4.13 × 10
-6 3.08 × 10
-5 3.03 × 10
-6 1.03 [38, 40]
Saquinavir 670 3.8 2.2 × 10
-6 1.21 × 10
-5 2.3 × 10
-5 7.15 × 10
-6 2.77 × 10
-5 4.95 × 10
-6 6.5 [38, 41]
Topotecan 421 0.8 1 × 10
-6 3.5 × 10
-6 1.2 × 10
-5 2.25 × 10
-6 2.35 × 10
-5 1.25 × 10
-6 2* [38, 42]
Verapamil 454 4.7 1.5 × 10
-5 1.5 × 10
-5 0* 1.5 × 10
-5 NA 0* NA [38, 43]
Talinolol 363.5 2.9 1.5 × 10
-6 1.5 × 10
-5 1.5 × 10
-5 6.0 × 10
-6 NA 4.50 × 10
-6 NA [38, 42, 43, 45]
Rifampicin 822 2.7 2.0 × 10
-6 8.4 × 10
-6 2.2 × 10
-5 5.2 × 10
-6 NA 3.20 × 10
-6 NA [38, 42, 43]
UK
224,671
544 1.8 3.0 × 10
-7 8.4 × 10
-6 9.1 × 10
-6 3.2 × 10
-6 9.43 × 10
-6 2.88 × 10
-6 32** [38, 42, 45]
a In Caco-2 experiments, the used drug concentration reported in Collett and coworkers [38] are 7.5 μM for saquinavir, 20 μM for verapamil and
rifampicin, 30 μM for paclitaxel and digoxin, 40 μM for topotecan, talinolol and UK 224,671
b In in vivo experiments, the dose administered to mice reported in Collett and coworkers [38] are 10 mg/kg of paclitaxel, 0.2 mg/kg of digoxin,
5 mg/kg of saquinavir and rifampicin, 2 mg/kg of UK 224,671, and 1 mg/kg of topotecan. Doses of verapamil and talinolol were not available.
c pH 7.5 used in Caco-2 experiments [38]
* No secretion; ** assuming that RAUC reflects plasma ratio [38]
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Papp, b-a, obtained in the presence and absence of P-gp
inhibitor, to estimate Pdiff, in-vitro and PP-gp, in-vitro for each
compound. Then, using S-Plus
®, we assessed the correla-
tions between in vivo Vmax(P-gp)/Km(P-gp) and PP-gp, in-vitro,
and between Pdiff, in-vivo and Pdiff, in-vitro values of the
drugs. These correlations are used to estimate apparent in
vivo efflux rate of domperidone from PP-gp, in-vitro
calculated in Step I.
As the tight junctions of the epithelium of the BBB
contribute to the reduction of drug diffusion through
this membrane, the diffusion velocity of the P-gp
substrate under study through BBB was not estimated
f r o mm e a s u r e m e n to fa p p a r e n tp e r m e a b i l i t yt h r o u g h
Caco-2 cells, but from in vitro m e a s u r e m e n to fi t s
permeability through bovine brain capillary endothelial
cells monolayer. This permeability value has been
assigned a weight factor of 150, as suggested by
Pardridge and coworkers [46] for in vitro permeability
compared to in vivo permeability values measured
in rats.
Step III: Calculation of the permeability-surface area product (PSAt)
and P-gp-mediated efflux clearance (CLP-gp, t) of the P-gp substrate
into mice brain and heart
The P-gp mediated efflux clearance has been found to be
tissue-dependent [47]. Thus, P-gp expression levels in
various tissues of WT mice [6] were used in our work to
account for this tissue specificity. Since the Caco-2 cells
line derives from human colon carcinoma and its
characteristics are similar to intestinal epithelial cells,
the intestinal tissue was chosen as the reference tissue for
P - g pe x p r e s s i o nl e v e l .I ne a c ho ft h eo t h e rm i c et i s s u e s ,
the P-gp expression level has been estimated as a fraction
of mice intestine P-gp expression (FP-gp, t,) and presented
in Table 3 [6]. We estimated CLP-gp, t,a n dP S A t both
expressed in L/min:
CLPgp, t St FPgp, t
Vmax   P-gp
Km   P-gp  
=× × ()
()
(24)
PSAt =P diff, in-vivo ×S t (25)
Assessing drug distribution in tissues expressing P-gp
To investigate the ability of the developed PBPK model
to assess the impact of P-gp activity modulation, we used
tissue concentration of
3H-domperidone measured in
adult male FVB WT and mdr1a/1b (-/-) KO mice after an
IV injection at the target dose of 5 mg/kg. Blood, plasma,
cerebral and cardiac tissue concentrations were available
at 4 and 120 min post dose, while WT liver concentra-
tions were available at 4, 7, 15, 30, 60 and 120 min post-
dose. While the accessible data set in heart and brain
tissues was limited in terms of the number of time
points, it had the potential of asserting the quality of the
model in those most strategic and informative regions of
the lineshape, ie, near the peak concentration and at the
elimination phase. We have also exploited a full data set
available for WT liver to encompass the important aspect
of hepatic disposition. The domperidone physicochem-
ical characteristics required as input parameters to the
model are extracted from literature [48-50]and presented
in Table 4.
Results
Estimation of metabolic parameters
Since the drug was administered intravenously, the liver
was considered as the only site of clearance by
metabolism. We extrapolated NCYP450 to a value of 14
nmol for a 30 g BW mouse from the log-log regression
calculated from published data [28] and presented in
Figure 3. The kinetic parameters of domperidone
biotransformation, Km(P450) and Vmax(P450),w e r ee s t i -
m a t e dt o1 3 0μM and 4.6 nmol/nmolP450/min,
respectively.
Table 3: Additional physiological parameters required for the MTB tissue models applied to brain and heart.
Tissue Vbl
a (mL/100 g tissue) St
b (dm
2/g tissue) FP-gp, t
c (-) ClP-gp, t
d (L/min) PSAt
e (L/min) Clout, OT
f (L/min)
Brain 2
g 2
h 0.42 3.71 × 10
-4 3.56 × 10
-5 2.8 × 10
-4
Heart 20
i 11.8
j 0.26 2.61 × 10
-4 1.2 × 10
-3 —
a Volume of blood in equilibrium with tissue
b Exchange surface area
c Relative fraction of mdr1a/1b mRNA expression in mice tissues compared to that in intestine, calculated from published data[6]. We calculated the
ratio of multidrug resistance PCR product to that of b-actin in each organ and we related these ratios to that obtained in mice intestine tissue.
d P-gp efflux clearance
e Permeability-Surface area product
f Parameter fitted to in vivo tissue concentrations
g Intermediate value of published values: 1.6 uL/g brain [29]; 0.94 ug/g [30]; 3 ug/g [31]
h Intermediate value of those published (1.50–2.40 dm
2/g tissue) [32, 33]
i Rat value [34]. Same ratio was found in guinea pigs [35]
j Human data applied to mice: Surface area of cardiac capillaries [36]
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MTB models
The tissue-to-plasma partition coefficients of domper-
idone determined by the tissue-composition-based-
approach [20] are listed in Table 1. Results of the
three-step procedure developed above to estimate PSAt
and CLP-gp, t rates of domperidone through blood-tissue
membrane are presented in Figure 4. Positive linear
correlations (Vmax(P-gp)/Km(P-gp) =4 . 7 5×P P-gp, in-vitro,
R
2 = 0.92, no intercept, S-Plus
®) were found between
Vmax(P-gp)/Km(P-gp) and PP-gp, in-vitro as well as between
Pdiff, in-vivo and Pdiff, in-vitro.( P diff, in-vivo =5 . 1×P diff, in-vitro,
R
2 = 0.89, no intercept, S-Plus
®). These correlations were
used to estimate Pdiff, in-vivo and Vmax(P-gp)/Km(P-gp) of
domperidone from PP-gp, in-vitro and Pdiff, in-vitro calculated
in Step I. Finally, the third step gave rise to values of
PSAt,a n dC L P-gp, t that we reported in Table 2 along with
values of St and FP-gp, t.
WS Model
The concentration-time profiles of domperidone simu-
lated in tissues using the WS model are presented in
Figure 5. Only tissues for which experimental data were
available are shown. The WS model successfully simu-
lated the time-concentration profile of domperidone in
hepatic tissue, indicating that the drug disposition in the
main eliminating organ was adequately characterized.
However, the WS model tends to overestimate domper-
idone concentrations in heart and brain tissues, which is
likely to be related to a poor estimation of tissue-to-
plasma partition coefficients for these tissues. The most
important over-prediction of drug concentration is
Table 4: Physico-chemical parameters of domperidone
Physico-chemical parameters Values References
Molecular weight 426 [48]
pKa 7.89 [48]
Octanol-Water partition coefficient (LogP) 3.35 EPIsuite [49]
Olive oil:water partition coefficient (LogP') 1.77
a [27]
Fraction unbound to plasma protein (fup) 0.08 [50]
Blood:plasma ratio (BP) 0.92 [50]
a Calculated from LogP' = (1.115 × LogP-1.35) [27]
Ln(NCYP450) = 0.7670 Ln(BW) + 5.3030
R
2 = 0.9519
p<0.0001
0
2
4
6
8
10
12
-2 -1 0 1 2 3 4 5 6
Ln(BW)
L
n
(
N
C
Y
P
4
5
0
)
Cattle
Sheep
Goat
Pig
Rabbit Rat
Figure 3
Log-Log relationship between the amount of hepatic
CYP450 and the body weight of various mammalian
species. Data from Craigmill et al., 2002 [28].
STEP III 
Calculation of permeability-surface area product 
and P-gp efflux rate (L/min) for various tissues: 
Cl P-gp,t  = Vmax(P-gp)/Km(P-gp)  FP-gp,t
                  PSAt  = Pdiff, in vivo   S t
 St  IN VIVO 
IN VITRO 
STEP II 
Estimation of the in vitro-in vivo correlation for 
the estimation of diffusion velocity of drugs 
(dm/min) through intestine membrane of mice. 
Data collected from Collett et al. [33] 
Pdiff, in vivo = a2. Pdiff,in vitro,
with a2 =5.1 ± 0.91  
STEP II 
Estimation of the in vitro-in vivo correlation for 
the estimation of P-gp efflux rate of drugs 
(dm/min) through intestine membrane of mice. 
Data collected from Collett et al. [33] 
Vmax(P-gp)/Km(P-gp) = a1 PP-gp,in vitro,
with a1 = 4.75 ± 0.52  
STEP I 
Estimation of in vitro diffusion velocity and P-gp 
efflux rate of domperidone through Caco-2 cells 
a)
from measurements of Papp,a-b and Papp, b-a [18] 
Pdiff, in vitro = (Papp, b-a+Papp, a-b)/2 =1.65 10
-4 dm/min 
PP-gp,in vitro = (Papp, b-a - Papp a-b)/2 =1.57 10
-4 dm/min
a)pH gradient from 6.5 to 7.4
In vivo diffusion velocity of 
domperidone through 
mouse intestine membrane 
Pdiff, in vivo
= 
8.4 10
-4 dm/min
Expression level of P-gp 
into various tissues 
relatively to gut tissue:  
FP-gp,t (%)
(See Table 3)
Exchange surface area of 
blood-tissue membranes 
expressing P-gp:
St (dm
2)
(See Table 3)
In vivo P-gp efflux rate of 
domperidone through mouse 
intestine membrane 
Vmax(P-gp)/Km(P-gp)
= 
7.5 10
-4 dm/min 
Figure 4
Illustration of the three-step procedure developed to
estimate in vivo apparent diffusion and P-gp efflux
rates of domperidone through capillary membrane of
the mouse brain and heart.
Figure 5
Prediction of tissue concentration of domperidone
using the WS model (black line) in any tissue/organ
included in the PBPK model. Tissue concentration
measured in WT mice (black lozenge) and KO mice (black
circle) after IV administration of 5 mg/kg of domperidone.
BLQ = Below Limit of Quantification.
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tion in this tissue, regardless of the mice strain, was 8.5
mg/L, compared to a maximum measured concentration
less than 0.03 mg/L and 0.22 mg/L, for WT mouse and
KO mouse, respectively. As, by definition, this model is
not suited to account for both active and passive
transport mechanisms effect on drug distribution, a
MTB model is applied to heart and brain tissues.
MTB Models: Accounting only for P-gp Efflux Activity in
Heart and Brain
P-gp has a protective function by limiting drug accumu-
lation into heart and brain tissues [1, 2]. Therefore, we
applied the MTB model to these tissues, and the WS
model to all other tissues. The PBPK simulation results
are illustrated in Figure 6. While the simulated effect of
P-gp tends to be slightly lower than the observed one,
the MTB model captures the peak concentration of
domperidone for both mice strains in heart tissue. These
results suggest that the apparent diffusion, rather than
active transport, is the main transport mechanism of
drug distribution in heart tissue. The MTB model
significantly improves the WS model results in brain
tissue, but it still tends to overestimate domperidone
terminal concentration. In light of the above results, we
were tempted to consider involvement of additional
efflux membrane transporters in domperidone distribu-
tion in brain tissue (Figure 7). We derived its efflux
clearance CLout, O by keeping diffusion and P-gp-
mediated efflux parameters identical to those used for
the brain MTB model while varying Clout, OT parameter
in order to fit simulated profiles to the available brain
concentrations. In this case, the simulated concentration-
time curves capture those terminal time points measured
in brain tissue of both mice strains, but fail to reproduce
the time-point concentration at 2 min post-dose. The
trend of drug concentration profile in brain tissue
simulated in the absence of P-gp activity but in the
presence of additional efflux transporter is now in
accordance with in vivo data (Figure 7, dashed line).
When compared to the WS model simulations, these
results suggest that the apparent passive and active
transport mechanisms are limiting processes of drug
distribution in brain tissue.
The PBPK model that has been retained at the end of the
modeling process comprises the MTB model for heart
and brain tissues, and the WS model for all other tissues.
W h e na p p l i e dt oh e a r tt i s s u e ,t h eM T Bm o d e li n v o l v e s
apparent passive diffusion and P-gp-mediated trans-
ports. For brain, the MTB model involves apparent
passive diffusion, P-gp mediated transports and a
potential additional efflux transport. However, this
assumption should be further studied through a sensi-
tivity analysis and additional in vitro and in vivo
experiments.
Discussion
The whole-body PBPK model developed herein aimed to
shed light, prior to in vivo experiments, on drug
distribution in tissues expressing ABC transporters, by
Figure 6
Prediction of tissue concentration of domperidone in
WT (black line) and KO (black dashed line) mice
using the mechanistic transport based tissue model
w i t hp a s s i v ea n dP - g pm e d i a t e de f f l u xt r a n s p o r t sf o r
heart and brain. Tissue concentration measured in WT
mice (black lozenge) and KO mice (black circle) after IV
administration of 5 mg/kg of domperidone. BLQ = Below
Limit of Quantification.
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(page number not for citation purposes)including apparent active and passive transport pro-
cesses. The model integrates the latest knowledge on the
most studied ABC membrane transporters expressed in
various tissues and organs. This is done by extrapolating
in vitro drug permeability measurements across cells
monolayers to in vivo conditions. This was performed
with a three-step procedure proposed and developed
herein, which allowed the estimation of the drug
transport-related parameters without having recourse to
data fitting. The proposed approach has to be used and
interpreted with some caution in terms of the considered
hypothesis and extrapolations. First, additional to P-gp,
Caco-2 system can also express other transporters such as
M R Pa n dO A T P s[ 5 1 ,5 2 ] .H e n c e ,t h ein vitro estimated
active transport rate may include the contribution of
these additional transporters. However, it may be
possible to isolate the effect of P-gp by adding a specific
P-gp inhibitor, when performing Caco-2 experiments.
Moreover, we have performed the in vitro-in vivo
regression analysis of apparent diffusion and efflux
t r a n s p o r tb yu s i n gar e s t r i c t e dd a t as e t[ 3 8 ] .O n c e
additional information regarding Caco-2 essays and
in vivo experiments using KO and WT mice becomes
available for additional compounds, the quality and
robustness of this analysis can be improved, reducing
thus the uncertainty pertaining to the extrapolation
procedure outside the range of permeability and drug
efflux used for the correlation.
This study focused on the mechanisms of drug distribu-
tion in non-eliminating tissues expressing P-gp trans-
porters, namely brain and heart. It was also prompted by
the need to improve the ability of the PBPK approach to
predict the impact of P-gp activity modulation on tissue
distribution of P-gp substrates. Indeed, while the clinical
importance of cardio-active agents in terms of efficacy
and toxicity is well acknowledged, kinetics of drug
transport into the myocardium has drawn little attention
so far. Since many cardiovascular active compounds are
subject to drug transport by ABC transporters, their
expression in heart may strongly influence therapeutic or
cardiotoxic effects [24]. However, the protective function
of P-gp in heart tissue was not obvious from the present
results.
Moreover, the multiplicity of drug transporters along
with their complex nature at the BBB prevent a better
understanding of the penetration mechanism of lipo-
philic compounds through this barrier [53]. Few
physiologically based models have been developed to
characterize drug distribution in brain tissues, mainly
because of the complex anatomy of the central nervous
system and the unavailability of physiological para-
meters [54, 55]. Whereas the mechanisms involved in
drug disposition into brain are not fully understood,
some authors [56] have raised the potential benefit of
using physiologically based compartment models to
determine the rate of entry of drugs into and their
distribution over the brain compartment. The proposed
PBPK model pointed out to the protective function of P-
gp against drug accumulation, which effect adds to the
existing passive transport at the BBB.
So far, standard PBPK models have been generally
composed of compartments that assume perfusion-rate
limited (WS), permeability-rate limited, or sometimes,
dispersion-rate limited models, the latter have not been
discussed here. The WS principle was applied in this
work as a first approximation model of drug distribution
in each tissue included in our PBPK model. The main
drawback of the WS model is its inability to capture the
effect of transporters activity on P-gp substrate disposi-
tion. In such a case, its application can underpredict or
overpredict drug concentration in target tissues [23]. This
has been confirmed in the present study where the main
deviation between the model predictions and the
measured concentration of domperidone was observed
in the brain tissue. This deviation can be attributed to the
bias in the estimated brain-to-plasma partition coeffi-
cient value [26] since this coefficient does not account
for active transport processes. Indeed, a significant
Figure 7
Prediction of brain concentration of domperidone in
WT (black line) and KO (black dashed line) mice
using the MTB tissue model with passive transport,
P-gp mediated efflux transport and additional efflux
transport model for brain. Tissue concentration
measured in WT mice (black lozenge) and KO mice (black
circle) after IV administration of 5 mg/kg of domperidone.
BLQ = Below Limit of Quantification.
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n o t i c e df o ra n o t h e rP - g ps u b s t r a t e ,d i a z e p a m[ 2 3 ] ,a n d
this bias translated into an overestimation of the brain
concentration-time profile by at least a factor of three.
However, this has neither been observed for ethoxyben-
zamide, a non-P-gp substrate, nor for propranolol [23], a
P-gp substrate [57]. In the case of propranolol, P-gp was
probably saturated [58, 59] at the concentrations used
[23], such that the diffusion process prevails on P-gp
efflux transport. All this suggests that the WS model does
not adequately describe disposition of P-gp substrate
drugs in tissues where P-gp, when not saturated, have a
significant protective function. Hence, it is natural to
consider transport-based mechanisms as the next step in
modeling domperidone distribution within the brain.
These transport mechanisms can occur at the capillary or
at the cellular membrane [12]. The cellular level of tissue
subdivision can be used to investigate the impact of
transporters activity modulation in drug distribution by
including an influx/efflux clearance term at the cellular
membrane [60]. However, this cellular subdivision asks
for an increased amount of information which is rarely
accessible without recurring to fitting procedures [12,
60]. In the proposed MTB model, we divided non-
eliminating tissues in two sub-compartments separated
by the capillary membrane, where apparent passive
diffusion and active transports occur, minimizing thus
physiological information needed for passive and P-gp
mediated active transports. This approach brings addi-
tional informative elements around the mechanisms
involved in drug distribution within non eliminating
tissues expressing P-gp.
Conclusion
This paper was devoted to set up the fundamental
mechanisms underlying distribution of drugs when
active transporters are involved. The latest knowledge
on P-gp transporters in heart and brain has been
integrated. The proposed PBPK model has been defined
for a mouse with average physiologic parameters,
extrapolated within species and using in vitro-in vivo
correlations. The next logical step in this process of
model development will be to explore the behaviour of
this PBPK model in terms of uncertainty and variability
of its parameters. With the progress in acquiring
quantitative knowledge on transporters, the procedure
proposed in this work could be adapted for different
drugs and transporters by taking into account their
intrinsic characteristics.
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